Insmed says to initiate phase 3 program for brensocatib in bronchiectasis by end of 2020

Insmed inc - new england journal of medicine publishes positive results from phase 2 willow study of brensocatib in patients with non-cystic fibrosis bronchiectasis.insmed - to initiate phase 3 program for brensocatib in bronchiectasis by end of 2020.insmed - results demonstrate potential clinical benefits of directly reducing neutrophil-mediated inflammation in bronchiectasis.insmed - results show brensocatib significantly prolonged time to 1st pulmonary exacerbation, over 24-week treatment for both doses versus placebo.insmed inc - brensocatib was generally well-tolerated in willow study.insmed - risk of exacerbation at any time during trial was reduced by 42% for 10 mg group versus placebo.insmed - treatment with brensocatib also reduced rate of pulmonary exacerbations, a key secondary endpoint.
INSM Ratings Summary
INSM Quant Ranking